Prometic Life Sciences Inc., of Laval, Quebec, entered an at-the-market equity distribution agreement with Canaccord Genuity Corp. to sell up to $50 million of common shares over the course of the next 16 months. Prometic plans to use the capital to fund ongoing operations and advance its lead drug candidates.